Allergies like asthma are very common which calls for even more therapeutic alternatives, other the ones used presently. Something known as histamine releasing factor (HRF) molecule is what experts from the La Jolla Institute for Allergy and Immunology claimed to have found. The team believed that the latter could supposedly serve as a target for allergy therapies.
The experts asserted that the HRF molecule contributed to asthma and few other allergies while they also stumbled upon a crucial receptor of the same. The professionals shared that the HRF molecule apparently communicated with antibodies known as IgE molecules which appeared to play a significant role in allergies. Two new peptides namely N19 and H3 were uncovered by the scientists which seemed to block the interactive actions between HRF and IgE, as observed in mice.
“Importantly, this work advances both the understanding of how HRF contributes to susceptibility of certain individuals in developing allergic disease as well as begins to unravel the mechanisms involved. What is most encouraging is the demonstration that the effect of HRF to enhance allergic responses can be blocked, thus suggesting the possibility of new therapeutic strategies in allergic diseases,” commented Juan Rivera, M.Sc., Ph.D., deputy scientific director at the National Institute of Arthritis and Musculoskeletal and Skin Diseases, part of the National Institutes of Health (NIH).
The researchers are optimistic of the preliminary results which essentially revealed that HRF inhibitors could help in the development of new remedial measures for allergies like asthma. This technique may most probably work for asthma patients who possess HRF reactive IgE.
The analysis is published in the Journal of Clinical Investigation.